Conjunctivitis 26 (2.1) 17 (1.4) 9 (0.7) 0 0 0 Eczema 25 (2.1) 24 (2.0) 1 (<0.1) 0 0 0 Depression 25 (2.1) 11 (0.9) 13 (1.1) 1 (<0.1) 0 0 Gastro-oesophageal reflux 25 (2.1) 17 (1.4) 7 (0.6) 1 (<0.1) 0 0 disease Data are (%) based on the total = 1215. TEAEs were defined as occurring between the first n N administration of study drug and 30 days after the last administration of study drug, inclusive. Patients were counted only once with each preferred term for the most severe case of that preferred term. TEAE = treatment-emergent adverse event. Supplementary Table S2. Most common TEAEs occurring in of patients by ≥20% Gorlin syndrome status. Number of patients with TEAEs, (%) n TEAE With Gorlin Without Gorlin Total = 219 = 990 = 1215 n n N Muscle spasm 171 (78.1) 635 (64.1) 807 (66.4) Alopecia 171 (78.1) 572 (57.8) 747 (61.5) Dysgeusia 127 (58.0) 533 (53.8) 663 (54.6) Weight decreased 98 (44.7) 393 (39.7) 493 (40.6) Decreased appetite 43 (19.6) 260 (26.3) 303 (24.9)
Conjunctivitis 26 (2.1) 17 (1.4) 9 (0.7) 0 0 0 Eczema 25 (2.1) 24 (2.0) 1 (<0.1) 0 0 0 Depression 25 (2.1) 11 (0.9) 13 (1.1) 1 (<0.1) 0 0 Gastro-oesophageal reflux disease 25 (2.1) 17 (1.4) 7 (0.6) 1 (<0.1) 0 0 Data are n (%) based on the total N = 1215. TEAEs were defined as occurring between the first administration of study drug and 30 days after the last administration of study drug, inclusive. Patients were counted only once with each preferred term for the most severe case of that preferred term. TEAE = treatment-emergent adverse event. Supplementary Table S2. Most common TEAEs occurring in ≥20% of patients by Gorlin syndrome status. TEAE Number of patients with TEAEs, n (%) With Gorlin n = 219 Without Gorlin n = 990 Total N = 1215 Muscle spasm 171 (78.1) 635 (64.1) 807 (66.4) Alopecia 171 (78.1) 572 (57.8) 747 (61.5) Dysgeusia 127 (58.0) 533 (53.8) 663 (54.6) Weight decreased 98 (44.7) 393 (39.7) 493 (40.6) Decreased appetite 43 (19.6) 260 (26.3) 303 (24.9)
1-s2.0-S0959804917312479-mmc1.docx